对比剂肾病早期诊断生物标志物的研究进展
被引量:2
摘要
随着放射诊断及冠状动脉介入诊疗技术的发展、人类预期寿命的延长,使用血管内对比剂的人群逐年增加。尽管上述人群中出现肾功能不全的患者不足1%,但在具有慢性肾病、糖尿病、使用。肾毒性药物等危险因素的患者中,使用对比剂后对比剂肾病(contrast induced nephropathy,CIN)的发生率高达25%,且有10%~12%最终需要肾替代治疗。
出处
《中国介入心脏病学杂志》
2016年第6期343-346,共4页
Chinese Journal of Interventional Cardiology
参考文献35
-
1Shaker OG, E1-Shehaby A, E1-Khatib M. Early diagnostic markers for contrast nephropathy in patients undergoing coronary angiography. Angiolngy, 2010,61 (8) :731-736.
-
2Tasanarong A, Hutayanon P, Piyayotai D. Urinary Neutrophil Gelatinase-Assoeiated Lipocalin predicts the severity of contrast- induced acute kidney injury in chronic kidney disease patients undergoing elective coronary procedures. BMC Nephrol, 2013, 14,270.
-
3Seeliger E, Sendeski M, Rihal CS, et al. Contrast-induced kidney injury : mechanisms, risk factors, and prevention. Eur Heart J, 2012, 33 (16) :2007-2015.
-
4Lane BR. Molecular markers of kidney injury. Urol Oncol, 2013, 31 (5) :682-685.
-
5Cruz DN, Goh CY, Haase-Fielitz A, et al. Early Biomarkers of Renal Injury. Congest Heart Fail, 2010, 16 (Suppl 1 ) :$25-31.
-
6Singer E, Mark6 L, Paragas N, et al. Neutrophil gelatinase- associated lipoealin: pathophysiology and clinical applications. ActaPhysiol ( Oxf), 2013, 207(4) :663-672.
-
7Alharazy SM, Kong N, Saidin R, et al. Neutrophil Gelafinase- Associated Lipocalin as an Early Marker of Contrast-Induced Nephropathy After Coronary Angiography. Angiology, 2014, 65 (3) :216-223.
-
8Ling W,Zhaohui N, Ben H, et al. Urinary IL-18 and NGAL as early predictive biomarkers in contrast-induced nephmpathy after coronary angiography. Nephron Clin Pract, 2008, 108 ( 3 ) : c176-181.
-
9MeCullough PA, Williams FJ, Stivers DN, et al. Neutrophil gelatinase-associated lipocalin: a novel marker of contrast nephropathy risk. Am J Nephrol, 2012, 35(6) :509-514.
-
10Malyszko J, Bachorzewska-Gajewska H, Poniatowski B, et al. Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease. Ren Fail, 2009, 31 (10) :910-919.
二级参考文献12
-
1Nguyen MT,Devarajan P.Biomarkers for the early detection of acute kidney injury[J].Pediatr Nephrol,2008,23:2151-2157.
-
2Stevens LA,Coresh J,Greene T,et al.Assessing kidney function:measured and estimated glomerular filtration rate[J].N Engl J Med,2006,354:2473-2483.
-
3Vaidya VS,Ramirez V,Ichimura T,et al.Urinary kidney injury molecule-1:a sensitive quantitative biomarker for early detection of kidney tubular injury[J].Am J Phvsol Renal Physiol,2006,290:F517-F529.
-
4Sudarsky D,Nikolsky E.Contrast-induced nephropathy in interventional cardiology[J].lnt J Nephrol Renovasc Dis,2011,4:85-99.
-
5Stacul F,Adam A,Becker CR,et al.Strategies to reduce the risk of contrast-induced nephropathy[J].Am J Cardiol,2006,98 (6A):59K-77K.
-
6Mishra J,Dent C,Tarabishi R,et al.Neutrophil gelatinaseassociated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery[J].Lancet,2005,365:1231-1238.
-
7Mishra J,Ma Q,Prada A,et al.Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury[J].J Am Soc Nephrol,2003,14:2534-2543.
-
8Malyszko J,Bachorzewska-Gajewska H,Poniatowski B,et al.Urinary and serum biomarkers after cardiac catheterization in diabetic patients with stable angina and without severe chronic kidney disease[J].Ren Fail,2009,31:910-919.
-
9Ichimura T,Asseldonk EJ,Humphreys BD,et al.Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells[J].J Clin Invest,2008,118:1657-1668.
-
10Ichimura T,Bonventre JV,Bailly V,et al.Kidney injury molecule-1 (KIM-1),a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain,is up-regulated in renal cells after injury[J].J Biol Chem,1998,273:4135-4142.
共引文献16
-
1易立勋,刘辉亮.NGAL、KIM-1和IL-18对创伤性肾损伤的早期诊断价值[J].海南医学院学报,2015,21(2):191-193. 被引量:11
-
2何阳,曹军,赵保成,刘洪强,郑晓辉,王赛博,罗剑均,颜志平.支气管动脉造影和栓塞术后造影剂肾病的危险因素分析[J].海南医学,2015,26(11):1589-1591. 被引量:1
-
3陈玉怡.强化阿托伐他汀预防急性冠脉综合征患者经皮冠脉介入治疗术后造影剂肾病的作用研究[J].中国医药导报,2015,12(18):114-118. 被引量:12
-
4迟骋,朱继红.中性粒细胞明胶酶相关脂质运载蛋白在心血管疾病中的应用价值[J].中华老年心脑血管病杂志,2015,17(8):886-888. 被引量:5
-
5邓楠,张大发.心脏术后急性肾损伤早期生物学标志物的研究进展[J].实用医学杂志,2015,31(22):3804-3806.
-
6李建华,赵宏娟,赵广平,甄书青,白玉伟,陈永学.尿白细胞介素18在腹腔热灌注化疗中的表达与血肌酐、尿素氮相关性的探讨[J].临床和实验医学杂志,2016,15(23):2353-2356.
-
7尤威,戚晨良,叶飞,黄胜兰,谢渡江,吴志明,黄凯,陈凯伦,黄天熠,陈绍良.尿中性粒细胞明胶酶相关脂质运载蛋白对对比剂肾病的早期诊断价值[J].中华心血管病杂志,2016,44(12):1024-1029. 被引量:10
-
8邓颖,葛平,计蕾.血清NT-proBNP及尿液NGAL水平对冠心病支架置入术患者对比剂肾病的早期预测价值[J].山东医药,2017,57(1):15-18. 被引量:7
-
9孙志刚,赵志红,马燕,葛平,邓颖.血清NT-proBNP、尿液NGAL对脓毒血症患儿继发急性肾损伤的早期预测价值[J].山东医药,2017,57(28):54-56. 被引量:21
-
10杜巍,胡大军,缪思斯.胱抑素C、视黄醇结合蛋白、α1微球蛋白和β2微球蛋白在对比剂肾病高危患者中的早期诊断价值[J].湘南学院学报(医学版),2017,19(3):1-5. 被引量:1
同被引文献9
-
1郭亭亭,刘芳.对比剂肾病的中西医防治[J].中西医结合心脑血管病杂志,2016,14(1):49-51. 被引量:5
-
2吴妍,李宁,曹雷.尿液NGAL与KIM-1检测对高胆红素血症新生儿早期肾损伤诊断价值的研究[J].标记免疫分析与临床,2016,23(3):271-274. 被引量:9
-
3汤志奇,龚婷.对比剂肾病的早期诊断新进展[J].临床肾脏病杂志,2016,16(5):317-319. 被引量:7
-
4汪玉琴,罗长青,王玉梅,李贞琼.血清胱抑素C评估对比剂肾病的Meta分析[J].临床肾脏病杂志,2016,16(10):589-593. 被引量:4
-
5何彩云,周少雄,沈永坚,邹林,黄丽姗.尿mALB、RBP、CysC及其联合检测在Ⅱ型糖尿病肾病早期诊断中的临床意义[J].国际检验医学杂志,2017,38(6):786-787. 被引量:15
-
6赵玉军.原发性高血压患者尿NGAL水平检测对肾功能损害的早期诊断价值[J].山东医药,2017,57(17):67-69. 被引量:9
-
7唐荣,敖翔,钟永,王睿苓,周巧玲.尿L-FABP与尿NGAL联合应用在儿童心脏术后急性肾损伤早期诊断中的价值[J].中国当代儿科杂志,2017,19(7):770-775. 被引量:22
-
8苗文清,王宇,杨俊,张义红,段会仙,赵仲文,汪艳.冠心病介入诊疗术后NGAL对造影剂肾病预测价值的相关性[J].昆明医科大学学报,2017,38(12):102-106. 被引量:5
-
9陈思,陈韵岱,钱赓,张华巍,李传威,石展.急性冠状动脉综合征患者冠脉造影术后对比剂肾病危险因素分析[J].中国循证心血管医学杂志,2016,8(6):742-745. 被引量:7
引证文献2
-
1艾民,刘广学,颜昌福,夏福纯,周双陆,贺剑.血清同型半胱氨酸与冠状动脉造影术后对比剂肾病的相关性研究[J].中国介入心脏病学杂志,2017,25(3):144-148. 被引量:7
-
2冯京全,柏明见,高智勇,赵明英.尿NGAL、KIM-1联合检测早期诊断对比剂肾病的价值研究[J].国际检验医学杂志,2019,40(3):355-358. 被引量:3
二级引证文献10
-
1常淑娟.急性冠状动脉综合征患者介入治疗后所致对比剂肾病的影响因素[J].中国民康医学,2018,30(1):15-16.
-
2薛玉,李静波,王莉娜.高同型半胱氨酸血症与冠脉造影术后对比剂肾病相关性的Meta分析[J].中国循证医学杂志,2018,18(7):700-706. 被引量:2
-
3王鹏,徐美华,崔莹,王霄,刘长江,饶小胖.高同型半胱氨酸血症与造影剂肾病关系的Meta分析[J].实用临床医学(江西),2018,19(7):4-7.
-
4卢海燕,吕玲春,沈珈谊,徐剑,吴小燕,韦铁民,纪建松.N氨基末端脑钠肽前体与冠状动脉造影后对比剂肾病相关性研究[J].介入放射学杂志,2018,27(9):817-821. 被引量:8
-
5边静,杨金容,汤雯.预见性护理联合水化疗法在预防老年血管造影患者并发对比剂肾病中的应用[J].齐鲁护理杂志,2019,25(12):76-78. 被引量:9
-
6瞿德涛,王忠,刘静.肾小球滤过率、血清胱抑素C、尿NAG酶联合诊断在预测PCI术后对比剂肾病中的意义[J].临床医学研究与实践,2019,4(29):123-125. 被引量:3
-
7宋醒良,程艳梅,黄俊,邵祥,徐金兰,鄢飞奔.中性粒细胞明胶酶相关脂质运载蛋白在心肾综合征中的早期诊断价值[J].中国当代医药,2019,26(27):143-146. 被引量:3
-
8黄美兰,姚茹,党小宁.全程精细化护理联合水化疗法预防糖尿病亚急性期脑梗死患者数字减影全脑血管造影术后对比剂肾病的疗效[J].现代中西医结合杂志,2019,28(34):3854-3858. 被引量:21
-
9李伟,于芬芬,季文萱,何晓艳,潘配强,孙艳,黄俊彦.对比剂肾病大鼠肾脏bax及bcl-2表达及羟苯磺酸钙干预研究[J].中国医药导报,2019,16(32):9-13. 被引量:1
-
10覃丽霞,尹彬,任盼,王静春,王玉芹,王春丽.蝉棒束孢菌子实体对大鼠肾小管上皮细胞的影响[J].菌物学报,2019,38(9):1501-1509.
-
1毛露霞,明艳,管素英.经桡动脉冠状动脉介入诊疗的护理[J].医学影像学杂志,2004,14(6):520-520.
-
2周华.经桡动脉行冠状动脉介入诊疗的护理[J].广西医学,2005,27(12):2062-2063.
-
3李顺宝,田春凤,李放.对比剂肾病研究进展[J].中国医药导刊,2014,16(11):1407-1409. 被引量:2
-
4彭泰松,许志高,武志峰,南喜文.未行肾替代治疗的慢性肾功能不全患者的尿毒症肺CT分级与血肌酐水平的关系[J].中国医学影像技术,2011,27(7):1388-1391. 被引量:3
-
5李建华,贺能树.碘对比剂肾病的预防措施[J].临床放射学杂志,2009,28(9):1331-1333. 被引量:5
-
6曹厚德.第二十届长城国际心脏病学会议关于对比剂肾病形成的专家共识[J].临床放射学杂志,2009,28(12):1634-1634. 被引量:3
-
7过去40年人类寿命延长超10岁[J].健康指南(中老年),2013(2):64-64.
-
8关李华,陈永生,梁海军.经桡动脉和股动脉途径行冠状动脉造影对比分析[J].中国实用医药,2009,4(24):29-31.
-
9王琼昕,曾和松.冠状动脉介入诊疗术中对比剂诱发肾病的研究进展[J].心血管病学进展,2008,29(6):889-891. 被引量:1
-
10张红霞.冠状动脉介入诊疗致术后低血压14例原因分析与护理[J].齐鲁护理杂志(上旬刊),2011,17(11):88-89. 被引量:1